Cover Image

CSF and plasma biomarkers in cerebral amyloid angiopathy: a single-center study and a systematic review/meta-analysis

Introduction: There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients co...

Full description

Saved in:
Bibliographic Details
Main Authors: Theodorou, Aikaterini (Author) , Tsantzali, Ioanna (Author) , Stefanou, Maria-Ioanna (Author) , Sacco, Simona (Author) , Katsanos, Aristeidis H (Author) , Shoamanesh, Ashkan (Author) , Karapanayiotides, Theodoros (Author) , Koutroulou, Ioanna (Author) , Stamati, Polyxeni (Author) , Werring, David J (Author) , Cordonnier, Charlotte (Author) , Palaiodimou, Lina (Author) , Zompola, Christina (Author) , Boviatsis, Efstathios (Author) , Stavrinou, Lampis (Author) , Frantzeskaki, Frantzeska (Author) , Steiner, Thorsten (Author) , Alexandrov, Andrei V (Author) , Paraskevas, Georgios P (Author) , Tsivgoulis, Georgios (Author)
Format: Article (Journal)
Language:English
Published: June 13, 2024
In: European stroke journal
Year: 2025, Volume: 10, Issue: 1, Pages: 278-288
ISSN:2396-9881
DOI:10.1177/23969873241260538
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1177/23969873241260538
Get full text
Author Notes:Aikaterini Theodorou, Ioanna Tsantzali, Maria-Ioanna Stefanou, Simona Sacco, Aristeidis H Katsanos, Ashkan Shoamanesh, Theodoros Karapanayiotides, Ioanna Koutroulou, Polyxeni Stamati, David J Werring, Charlotte Cordonnier, Lina Palaiodimou, Christina Zompola, Efstathios Boviatsis, Lampis Stavrinou, Frantzeska Frantzeskaki, Thorsten Steiner, Andrei V Alexandrov, Georgios P Paraskevas and Georgios Tsivgoulis
Description
Summary:Introduction: There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients compared to healthy controls (HC) and patients with Alzheimer Disease (AD). - Patients and methods: A systematic review and meta-analysis of published studies, including also a 5 year single-center cohort study, with available data on CSF and plasma biomarkers in symptomatic sporadic CAA versus HC and AD was conducted. Biomarkers’ comparisons were investigated using random-effects models based on the ratio of mean (RoM) biomarker concentrations. RoM < 1 and RoM > 1 indicate lower and higher biomarker concentration in CAA compared to another population, respectively. - Results: We identified nine cohorts, comprising 327 CAA patients (mean age: 71 ± 5 years; women: 45%) versus 336 HC (mean age: 65 ± 5 years; women: 45%) and 384 AD patients (mean age: 68 ± 3 years; women: 53%) with available data on CSF biomarkers. CSF Aβ42 levels [RoM: 0.47; 95% CI: 0.36-0.62; p < 0.0001], Aβ40 levels [RoM: 0.70; 95% CI: 0.63-0.79; p < 0.0001] and the ratio Aβ42/Aβ40 [RoM: 0.62; 95% CI: 0.39-0.98; p = 0.0438] differentiated CAA from HC. CSF Aβ40 levels [RoM: 0.73; 95% CI: 0.64-0.83; p = 0.0003] differentiated CAA from AD. CSF tau and p-tau levels differentiated CAA from HC [RoM: 1.71; 95% CI: 1.41-2.09; p = 0.0002 and RoM: 1.44; 95% CI: 1.20-1.73; p = 0.0014, respectively] and from AD [RoM: 0.65; 95% CI: 0.58-0.72; p < 0.0001 and RoM: 0.64; 95% CI: 0.57-0.71; p < 0.0001, respectively]. Plasma Aβ42 [RoM: 1.14; 95% CI: 0.89-1.45; p = 0.2079] and Aβ40 [RoM: 1.07; 95% CI: 0.91-1.25; p = 0.3306] levels were comparable between CAA and HC. - Conclusions: CAA is characterized by a distinct CSF biomarker pattern compared to HC and AD. CSF Aβ40 levels are lower in CAA compared to HC and AD, while tau and p-tau levels are higher in CAA compared to HC, but lower in comparison to AD patients.
Item Description:Gesehen am 02.12.2024
Physical Description:Online Resource
ISSN:2396-9881
DOI:10.1177/23969873241260538

Similar Items